Quell® Opioid Reduction and Pain Relief in Patients with Cancer
According to the National Cancer Institute, about 15 million Americans are living with cancer or have a history of cancer. In these patients, chronic pain is one of the most feared and challenging symptoms. Unfortunately, the prevalence of pain is over 50% in most forms of cancer. Prescription opioids are the mainstay of the medical management of moderate to severe cancer pain. However, given the side effects and the stigma of opioid use, there is growing interest in alternative approaches to managing cancer related pain.
Together with NeuroMetrix, Inc., the Scripps Translational Science Institute (STSI) is conducting a clinical study to assess the impact of the Quell® wearable pain relief technology. Quell utilizes neurostimulation technology to provide relief from chronic pain. The wearable device is lightweight and can be worn during the day while active, and at night while sleeping.
This 10-week study will enroll 40 adult patients who have been diagnosed with metastatic breast, prostate or colorectal cancer, and who use at least one opioid medication on a daily basis.